膀胱癌新型DNA适配体Apt71的筛选鉴定和致癌机理的研究
结题报告
批准号:
81972390
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
李翀
学科分类:
肿瘤靶向治疗
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
李翀
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
特异的肿瘤标志物一直是膀胱癌研究的热点。我们用全新的膀胱癌新靶标AG-CD71筛选到一条高特异性和高灵敏度的核酸适配体Apt71。Apt71对人膀胱癌组织和膀胱癌细胞系呈强阳性反应,而与正常人膀胱组织和非膀胱癌肿瘤细胞呈阴性反应,与正常人胚胎组织和其它正常组织也无交叉反应。在细胞水平和动物水平,Apt71能有效控制肿瘤细胞的增殖、迁移、粘附和侵袭,显著抑制裸鼠移植瘤的生长。本课题将在Apt71识别新靶标AG-CD71的基础上,探明其在膀胱癌细胞中的主要信号通路,研究其在膀胱癌不同病理分期与肿瘤分级中的表达差异,最终阐明Apt71所识别的新靶标在膀胱癌中的致癌机理,建立膀胱癌早期预警和预后监测系统,为膀胱癌体外诊断及靶向治疗提供理论和实验依据。
英文摘要
Tumor markers with specificity have long been a hot topic in bladder cancer research. With the adoption of a novel bladder cancer target AG-CD71, we have screened a nuclear acid aptamer (Apt71) of high specificity and sensitivity, which is strongly positive for human bladder cancer tissues and bladder cancer cell lines, but negative for normal human bladder tissues and non-bladder cancer tumor and showing no cross-reactivity with normal human embryonic tissues and other normal tissues. At both the cellular level and animal level, Apt71 could effectively control the proliferation, migration, adhesion and invasion of tumor cells, and significantly inhibit the growth of xenografts in nude mice. Based on the fact that, Apt71 could identify the new target AG-CD71, this project is conducted to explore the major signal pathway of Apt71 in bladder cancer cells, to study its differential expressions in bladder cancer of different pathological stages and tumor staging, and finally to illustrate the carcinogenesis of the new target identified by Apt71 in bladder cancer with the purpose of constructing a system including early warning and prognosis monitoring of bladder cancer and providing theoretical and experimental basis for in vitro diagnosis and targeted therapy of bladder cancer.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:--
发表时间:2020
期刊:Cancer Lett
影响因子:--
作者:Yi Li;Gang Li;Xiangyang Guo;Haochen Yao;Guoqing Wang;Chong Li
通讯作者:Chong Li
Aberrantly glycosylated integrin α3β1 is a unique urinary biomarker for the diagnosis of bladder cancer
异常糖基化整合素α3β1 是诊断膀胱癌的独特尿液生物标志物
DOI:10.18632/aging.103297
发表时间:2020
期刊:Aging-US
影响因子:5.2
作者:Di Jin;Ruiyun Zhang;Haige Chen;Chong Li
通讯作者:Chong Li
Frontiers in Bladder Cancer Genomic Research.
膀胱癌基因组研究的前沿。
DOI:10.3389/fonc.2021.670729
发表时间:2021
期刊:Frontiers in oncology
影响因子:4.7
作者:Li Y;Sun L;Guo X;Mo N;Zhang J;Li C
通讯作者:Li C
Systemic immune effects of anesthetics and their intracellular targets in tumors.
麻醉药及其细胞内靶标对肿瘤的系统免疫作用
DOI:10.3389/fmed.2022.810189
发表时间:2022
期刊:FRONTIERS IN MEDICINE
影响因子:3.9
作者:Luan, Ting;Li, Yi;Sun, Lihui;Xu, Siqi;Wang, Haifeng;Wang, Jiansong;Li, Chong
通讯作者:Li, Chong
Cancer stem cell-specific expression profiles reveal emerging bladder cancer biomarkers and identify circRNA_103809 as an important regulator in bladder cancer
癌症干细胞特异性表达谱揭示了新兴的膀胱癌生物标志物,并将 circRNA_103809 确定为膀胱癌的重要调节因子
DOI:10.18632/aging.102816
发表时间:2020-02-29
期刊:AGING-US
影响因子:5.2
作者:Tao, Tao;Yuan, Simin;Wu, Song
通讯作者:Wu, Song
CCP6介导的谷氨酸化修饰调控膀胱癌干细胞自我更新及其肿瘤干预的分子机制研究
长链非编码RNA lncAC1调控膀胱癌干细胞自我更新的分子机制研究
膀胱癌特异性肿瘤标志物的筛选鉴定和致癌机理的研究
国内基金
海外基金